Brepocitinib

PubChem compound: 118878093

Active ingredient description

Brepocitinib is a Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor. The JAK family comprises cytoplasmic tyrosine kinases that mediate signal transduction of cytokine receptors to influence immune cell function. The relevance of inhibition of specific JAK combinations to therapeutic effectiveness is not known.

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Document Type Information Source  
 LISRAYA Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

DrugBank Drug: DB15003
KEGG Drug: D11537
PubChem Compound: 118878093
UNII Identifier: 3X8387Q25N
BREPOCITINIB

Medicines

Brepocitinib is an active ingredient of these brands:

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈